The DISCUSS project: Induced pluripotent stem cell lines from previously collected research biospecimens and informed consent: Points to consider

Stem Cells Translational Medicine

Volumn 2, Issue 10, 2013, Pages 727-730

  Lomax, Geoffrey P ^a   Hull, Sara Chandros ^b,c   Lowenthal, Justin ^c   Rao, Mahendra ^d,e   Isasi, Rosario ^f  

^a California Institute for Regenerative Medicine   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c CLINICAL CENTER   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG INDUSTRY; GENETICS; GENOTYPE; HEALTH CARE POLICY; HUMAN; INFORMED CONSENT; MEDICAL RESEARCH; NATIONAL HEALTH ORGANIZATION; ORGAN TRANSPLANTATION; PLURIPOTENT STEM CELL; PRACTICE GUIDELINE; STEM CELL RESEARCH;

EID: 84884808181     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0099     Document Type: Article

References (12)

1. Lowenthal J, Lipnick S, Rao MS et al. Specimen collection for induced pluripotent stem cell research: Harmonizing the approach to informed consent. Stem Cells Translational Medicine 2012;1:409-421.
2. National Research Council and Institute of Medicine. Final Report of the National Academies' Human Embryonic Stem Cell Research Advisory Committee and 2010 Amendments to the National Academies' Guidelines for Human Embryonic Stem Cell Research. National Academy Press. Available at http://nas-sites.org/ stemcells/. Accessed May 7, 2013.
3. Isasi RM, Knoppers BM. Governing stem cell banks and registries: Emerging issues. Stem Cell Res 2009;3:96-105.
4. U.S. Department of Health and Human Services. Protection of Human Subjects. 45. CFR. 46. Available at http://nas-sites.org/ stemcells/. Accessed May 7, 2013.
5. U.S. Department of Health and Human Services. OHRP: Guidance on research involving coded private information or biological specimens. October 16, 2008. Available at http:// www.hhs.gov/ohrp/policy/cdebiol.html. Accessed May 7, 2013.
6. Knoppers BM, Isasi R, Benvenisty N et al. Publishing SNP genotypes of human embryonic stem cell lines: Policy statement of the International Stem Cell Forum Ethics Working Party. Stem Cell Rev 2011;7:482-484.
7. Lomax GP, Peckman SR. Stem cell policy exceptionalism: Proceed with caution. Stem Cell Rev 2012;8:299-304.
8. Lowenthal J, Hull SC. Framing the "right to withdraw" in the use of biospecimens for iPSC research. Ethics Biol Eng Med (in press).
9. Medical Accountability Standards Working Group. Ethicalandpolicy considerations for a pluripotent cell resource center 2011 update. Los Angeles, CA: California Institute for Regenerative Medicine. June 28, 2011. Available at http://www.cirm.ca.gov/sites/default/ files/files/about_cirm/SWG_April_2011_6_ 28_2011.pdf. Accessed April 22, 2013.
10. Isasi R, Knoppers BM, Lomax G. Sustained interaction: The new normal for stem cell repositories? Regen Med 2011;6:783-792.
11. Lomax GP, Shepark KA. Return of results in translational iPS cell research: Considerations for donor informed consent. Stem Cell Res Ther 2013;4:6.
12. Isasi R, Knoppers BM, Andrews PW et al. Disclosure and management of research findings in stem cell research and banking: Policy statement. Regen Med 2012;7: 439-448.